Studies have shown that a higher BMI associated with improved PFS and OS and a higher incidence of irAEs in cancer patients receiving PD-1/PD-L1 inhibitors (40–42), suggesting that adipose tissue may play a key role in immunotherapy and irAEs. This evidence concerns the gene PDCD1 and cancer.